Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) on Thursday, setting a price target of $125, which is approximately 26.01% below the present share price of $168.95.
Schwartz expects Sarepta Therapeutics to post earnings per share (EPS) of -$2.50 for the first quarter of 2021.
The current consensus among 14 TipRanks analysts is for a Strong Buy rating of shares in Sarepta Therapeutics, with an average price target of $178.42.
The analysts price targets range from a high of $215 to a low of $125.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $143.92 million and a net profit of -$137.07 million. The company's market cap is $13.33 billion.
According to TipRanks.com, Leerink Partners analyst Joseph Schwartz is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.2% and a 53.72% success rate.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.